

# NFP Hospitals H2 2015 Update

---

**George Huang**

Senior Analyst/Director

[george.huang@wellsfargo.com](mailto:george.huang@wellsfargo.com)

212.214.5061

July 16, 2015

Please see the disclosure appendix of this publication for certification and disclosure information. All estimates/forecasts are as of 7/16/15 unless otherwise stated.

**Together we'll go far**



# Some Sector Risks Stabilizing

## Political and Legal Challenges

- SCOTUS decision to uphold federal health insurance exchange (HIE) premium subsidies provides stability for hospital strategic and operational planning
- ACA key 2016 presidential election issue; but no consensus on Republican “repeal and replace” plans
- Minor ACA amendments are still being pursued by Congress, but a repeal of 2.3% medical device tax and IPAB would require bipartisan compromises on other priorities

## Health Insurance Exchanges

- 2015 effectuated enrollment of 10.2 million (as of March 31) exceeds the 9.1 million HHS year-end target
- Utilization and revenue improvement from the newly insured, but also bad debt from high-deductibles
- Further HIE enrollment growth likely as individual mandate penalties increase
- However, adverse selection risk remains: 1) future competitive premium pricing critical 2) continued lack of consumer awareness and poor health care/health insurance literacy

## Medicaid Expansion

- Optional Medicaid expansion has limited implementation - only 28 states and Washington, D.C., have opted in so far (MT plan needs CMS waiver approval)
- However, we continue to believe most states are pragmatic and are likely to eventually opt in
- At least seven state governors (AL, AK, MO, SD, TN, UT, VA, and WY) are currently open to expansion, but may lack sufficient state legislative support

## Capital Markets

- H1 2015 hospital bond volume was up dramatically: \$17.6 billion (87.5% YoY)
- About 80% was refunding/combined money deals, so issuance pace likely to slow when rates rise
- Technical, rather than credit factors continue to drive market
- Hospital credit risk remains underpriced, but S&P Municipal Bond Hospital Index still outperformed other muni asset classes on a total return basis: 0.83% (YTD), 5.17% (1-year), 12.54% (2014)

# Some Sector Risks Still Evolving

## Reimbursement Pressures

- Reductions to hospital reimbursement contributing to margin compression:
  - Medicare sequestration, ACA's scheduled Medicare cuts, but Medicaid DSH cuts delayed to 2018
  - State Medicaid rate and/or scope of service reductions; changes in traditional eligibility criteria
- Pressure to increase operating efficiency despite increasing reform-related expenses
- Reduced ability to cost shift; commercial payor pushback

## Federal Budget Deficit

- Health care cost-containment remains a priority for all politicians
- Hospitals remain a target for further reimbursement cuts
- Annual health care expenditure growth of 6.0% expected through 2023 (CMS)
- The population, aged 65 or older, is expected to increase by more than 82% by 2039 (CBO)

## Industry in Transition

- Challenging transition period, as the industry continues to move away from fee-for-service
- Delivery system reforms unlikely to be reversed regardless of ACA status
- New patient utilization patterns due to HIEs and Medicaid expansion
- Profitability unclear - new HIE and Medicaid revenues may not offset top-line reimbursement cuts

## Consumerism

- Price transparency and care quality movements limit patient utilization growth and revenue potential
- Increased cost sharing for ESI and more high-deductible health plans (HDHPs) reduce "excess" utilization but also contribute to bad debt
- Reform-driven delivery system changes and emphasis on value/quality-based care over volume
- Continued shift to greater outpatient service mix and more cost-appropriate care options

# Medicaid Expansion Has Helped Hospitals

## ➤ Hospitals in opt-out states more likely to underperform those in states expanding Medicaid

- Opt-out states concentrated in the South and Midwest regions
- Hospitals in the South challenged by: 1) poorer population health status and healthy life expectancy 2) higher poverty and uninsured rates 3) less generous traditional Medicaid eligibility levels and scope of coverage
- Two-thirds of rural hospital closures over the past five years have been in the South
- **Estimated 4.2 million more uninsured if no other states expand Medicaid in 2016 (Urban Institute)**

## ➤ Faster than expected Medicaid enrollment pace

- 71.1 million total Medicaid enrollments (as of April 2015)
- An increase of 12.3 million (up 21.3%) over average monthly enrollments prior to ACA's 2014 open enrollment period
- Slower gains in "oppositional" states

Expansion States	Non-Expansion States
• 28.2% growth in enrollments	• 8.8% growth in enrollments
• 10.9% uninsured rate in 2014	• 16% uninsured rate in 2014
• 4.0 percentage point decline from 2013	• 2.4 percentage points decline from 2013

Sources: U.S. Department of Health & Human Services, Centers for Disease Control and Well Fargo Securities, LLC

## ➤ Positive early effects of ACA expansion - Ascension Health case study (Kaiser)

- Hospitals in expansion states benefited more from Medicaid expansion than HIE enrollments
- Hospitals in non-expansion states experienced noticeably less improvement in payor mix

Expansion State Hospitals	Non-Expansion State Hospitals
• 7.4% increase in Medicaid discharges	• 1.4% increase Medicaid discharges
• 32.2% decline uninsured/self-pay volumes	• 4.4% decline uninsured/self pay volumes
• 8.2% increase Medicaid gross revenues	• 9.4% decline Medicaid gross revenues
• 63.2% decline self-pay revenues	• 2.6% increase self-pay revenues
• 40.1% decline charity care costs	• 6.2% decline charity care costs
• 6.3% net decline uncompensated care costs	• 11.8% net increase uncompensated care costs

Source: Kaiser Commission on Medicaid and Uninsured and Well Fargo Securities, LLC

# Hospitals Adapting to Consumerism

- **Hospitals must lower their cost structures and reorient their strategies to improve pricing/billing, quality performance, marketing/communications, as well as enhance patient engagement**

## **Increased patient focus on cost, value and customer service**

- HDHPs limit utilization and costs
- More patient engagement, involvement in decision-making, and “shopping” for health care
- **Increased price sensitivity**
- **“Consumer paradox”** - slower historical health care cost growth, yet consumer perception of faster cost growth (employee share of costs growing faster than income)

## **HIE plan effects**

- Less profitable than ESI plans
- Higher cost-sharing requirements (deductibles and out-of-pocket maximums) leading to bad debt
- Affordability remains the No. 1 criteria; 85% of enrollees selected subsidy eligible plans

## **Newly insured HIE patients showed positive changes in utilization and personal responsibility (HCA)**

- 2x more likely to seek outpatient care than uninsured
- More financially responsible (\$390 average payment) vs. uninsured (89.6% zero pay)
- Uninsured 3x as likely to use ER as newly insured HIE patients

## **Narrow networks “work,” but threaten high-cost providers like academic medical centers, children’s and cancer hospitals**

- Effective cost control tool
- High-cost providers vulnerable because low-cost, high-quality hospitals favored
- More highly integrated hospitals better at coordinating care and have continuum to put patients in cost-appropriate setting
- 23% of employers used narrow, tiered or high-performance networks in 2013; more evaluating these plan designs
- Broader network plans had 26% higher prices than narrow networks (McKinsey)

# Q&A

- **Other topics, interests or questions?**
- **Suggestions?**
- **Where to Find Our Research:**
  - Reports are available at [www.wellsfargoresearch.com](http://www.wellsfargoresearch.com)
  - On Bloomberg at WFRE
  - Also now available on Markit Hub ([www.hub.com](http://www.hub.com))
  - If you would like to be added to our email distribution list, send us a note.

## **DISCLOSURE APPENDIX**

### **Analyst's Certification**

The research analyst(s) principally responsible for the report certifies to the following: all views expressed in this research report accurately reflect the analysts' personal views about any and all of the subject securities or issuers discussed; and no part of the research analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the research analyst(s) in this research report.

### **Important Disclosures Relating to Conflicts of Interest and Potential Conflicts of Interest**

Wells Fargo Securities does not compensate its research analysts based on specific investment banking transactions. Wells Fargo Securities research analysts receive compensation that is based on and affected by the overall profitability of their respective department and the firm, which includes, but is not limited to, investment banking revenue. Wells Fargo Securities may sell or buy the subject securities to/from customers on a principal basis or act as a liquidity provider in such securities.

Wells Fargo Securities Fixed Income Research analysts interact with the firm's trading and sales personnel in the ordinary course of business. The firm trades or may trade as a principal in the securities or related derivatives mentioned herein. The firm's interests may conflict with the interests of investors in those instruments.

**Additional information is available on request.**

### **About Wells Fargo Securities**

Wells Fargo Securities is the global brand name for the capital markets and investment banking services of Wells Fargo & Company and its subsidiaries, including but not limited to Wells Fargo Securities, LLC, a U.S. broker-dealer registered with the U.S. Securities and Exchange Commission and a member of NYSE, FINRA, NFA and SIPC, Wells Fargo Institutional Securities, LLC, a member of FINRA and SIPC, Wells Fargo Prime Services, LLC, a member of FINRA, NFA and SIPC, Wells Fargo Bank, N.A. and Wells Fargo Securities International Limited, a U.K. entity investment firm authorized and regulated by the Financial Conduct Authority. The Wells Fargo Securities legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. Non-US analysts may not be associated persons of Wells Fargo Securities, LLC. and therefore may not be subject to NASD Rule 2711/NYSE Rules 472 restrictions on communications with subject company, public appearances and trading securities by the analysts, but will be subject to their own local regulatory requirements.

### **Notice to U.S. Investors**

Unless prohibited by the provisions of Regulation S of the 1933 Act, this material is distributed in the U.S., by Wells Fargo Securities, LLC, which takes responsibility for its contents in accordance with the provisions of Rule 15a-6 and the guidance thereunder, under the U.S. Securities Exchange Act of 1934. Any transactions in securities identified herein may be effected only with or through Wells Fargo Securities, LLC.

### **Important Information for Non-U.S. Clients**

#### **EEA**

The securities and related financial instruments described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. For recipients in the EEA, Wells Fargo Securities International Limited ("WFSIL") disseminates Research which has been approved for the purposes of Section 21 of the Financial Services and Markets Act 2000 ("the Act"). WFSIL is a U.K. incorporated investment firm authorized and regulated by the Financial Conduct Authority. For the purposes of Section 21 of the Act, WFSIL does not deal with retail clients. The FCA rules made under the Financial Services and Markets Act 2000 for the protection of retail clients will therefore not apply, nor will the Financial Services Compensation Scheme be available. This report is not intended for, and should not be relied upon by, retail clients.

### **Australia**

Each of Wells Fargo Securities, LLC, Wells Fargo Securities Asia Limited and Wells Fargo Securities International Limited is exempt from the requirements to hold an Australian financial services license in respect of the financial services it provides to wholesale clients in Australia. Wells Fargo Securities, LLC is regulated under U.S. laws, Wells Fargo Securities Asia Limited is regulated under Hong Kong law, and Wells Fargo Securities International Limited is regulated under U.K. law, all of which differ from Australian laws. Any offer or documentation provided to Australian recipients by Wells Fargo Securities in the course of providing the financial services will be prepared in accordance with the laws of the United States, Hong Kong or U.K. and not Australian laws.

### **Hong Kong**

This report is issued and distributed in Hong Kong by Wells Fargo Securities Asia Limited (“WFSAL”), a Hong Kong incorporated investment firm licensed and regulated by the Securities and Futures Commission to carry on types 1, 4, 6 and 9 regulated activities (as defined in the Securities and Futures Ordinance (Cap. 571 of The Laws of Hong Kong), “the SFO”). This report is not intended for, and should not be relied on by, any person other than professional investors (as defined in the SFO). Any securities and related financial instruments described herein are not intended for sale, nor will be sold, to any person other than professional investors (as defined in the SFO). The author or authors of this report is or are not licensed by the SFC. Professional investors who receive this report should direct any queries regarding its contents to Mark Jones at WFSAL (email: wfsalresearch@wellsfargo.com).

### **Japan**

This report is distributed in Japan by Wells Fargo Securities (Japan) Co., Ltd, registered with the Kanto Local Finance Bureau to conduct broking and dealing of type 1 and type 2 financial instruments and agency or intermediary service for entry into investment advisory or discretionary investment contracts. This report is intended for distribution only to professional investors (Tokutei Tousehika) and is not intended for, and should not be relied upon by, ordinary customers (Ippan Tousehika).

The ratings stated on the document are not provided by rating agencies registered with the Financial Services Agency of Japan (JFSA) but by group companies of JFSA-registered rating agencies. These group companies may include Moody's Investors Services Inc, Standard & Poor's Rating Services and/or Fitch Ratings. Any decisions to invest in securities or transactions should be made after reviewing policies and methodologies used for assigning credit ratings and assumptions, significance and limitations of the credit ratings stated on the respective rating agencies' websites.

**This report, IDs, additional disclosure information and passwords are available at [www.wellsfargoresearch.com](http://www.wellsfargoresearch.com).**

This report is for your information only and is not an offer to sell, or a solicitation of an offer to buy, the securities or instruments named or described in this report. Interested parties are advised to contact the Wells Fargo entity in their local jurisdiction with which they deal, or the entity that provided this report to them, if they desire further information or if they wish to effect transactions in the security discussed in this report. The information in this report has been obtained or derived from sources believed by Wells Fargo Securities, to be reliable, but Wells Fargo Securities does not represent that this information is accurate or complete. Certain text, images, graphics, screenshots and audio or video clips included in this report are protected by copyright law and owned by third parties (collectively, “Third Party Content”). Third Party Content is made available to clients by Wells Fargo under license or otherwise in accordance with applicable law. Any use or publication of Third Party Content included in this report for purposes other than fair use requires permission from the copyright owner. Any opinions or estimates contained in this report represent the judgment of Wells Fargo Securities at this time, and are subject to change without notice. For the purposes of the U.K. Financial Conduct Authority's rules, this report constitutes impartial investment and substantive research. Each of Wells Fargo Securities, LLC, and Wells Fargo Securities International Limited is a separate legal entity and distinct from affiliated banks. Copyright © 2015 Wells Fargo Securities, LLC.

SECURITIES: NOT FDIC-INSURED \* NOT BANK-GUARANTEED \* MAY LOSE VALUE